Publications

Journal Article
Research Support, Non-U.S. Gov't Review
Ppublish 1131 citations
Electronic publication date
September 29, 2009

View on Pubmed.gov 19693097 | View on doi.org 10.1038/nrc2693

When mutants gain new powers: news from the mutant p53 field.

Search for publications in this journal Nat Rev Cancer - 9(10):701-13

Abstract

Ample data indicate that mutant p53 proteins not only lose their tumour suppressive functions, but also gain new abilities that promote tumorigenesis. Moreover, recent studies have modified our view of mutant p53 proteins, portraying them not as inert mutants, but rather as regulated proteins that influence the cancer cell transcriptome and phenotype. This influence is clinically manifested as association of TP53 mutations with poor prognosis and drug resistance in a growing array of malignancies. Here, we review recent studies on mutant p53 regulation, gain-of-function mechanisms, transcriptional effects and prognostic association, with a focus on the clinical implications of these findings.

References

Nature. 1995 Nov 9;378(6553):206-8

Oncogene. 1998 Sep 3;17(9):1061-8

Biotechniques. 2005 Nov;39(5):755-61

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8424-9

Cited by 1131 citations (total)

Journal Article Research Support, Non-U.S. Gov't

p53 Gene repair with zinc finger nucleases optimised by yeast 1-hybrid and validated by Solexa sequencing.

Electronic publication date October 22, 2011

Search for publications in this journal PLoS One

Frank Herrmann [...] Mark Isalan et al.

The tumor suppressor gene p53 is mutated or deleted in over 50% of human tumors. As functional p53 plays a...

Journal Article Review

Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis.

Electronic publication date February 17, 2010

Search for publications in this journal Nat Rev Cancer

Brian J Reid [...] Thomas L Vaughan et al.

The public health importance of Barrett's oesophagus lies in its association with oesophageal adenocarcinoma. The incidence of oesophageal adenocarcinoma has...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances